Back
Science

U.S. Experiences Severe Flu Season with Elevated Activity and Shifting Federal Vaccine Guidance

Generated on: Last updated: 15 sources
View source

United States Grapples with Severe Flu Season Amidst Shifting Vaccine Guidance

The United States is currently battling a severe and historically high flu season, marked by a significant surge in illnesses, hospitalizations, and deaths. Health officials and data from the Centers for Disease Control and Prevention (CDC) confirm elevated influenza activity across most states, with outpatient visits for flu-like illnesses reaching levels not seen in decades. This season is largely driven by a variant of the H3N2 virus, which has shown a "mismatch" with the current vaccine formulation. Concurrent with this intense flu season, federal agencies have adjusted childhood immunization guidelines, shifting routine flu vaccine recommendations to a "shared clinical decision-making" approach.

Flu Activity Overview and Historical Severity

U.S. flu activity has been characterized as severe, high, or very high, reaching levels not observed in over 25 years by certain measures. As of late December, 45 states reported high or very high flu activity, a figure that remained widespread through January, with 29 states reporting high or very high levels by late January.

Outpatient visits for flu-like illnesses, defined as a fever accompanied by a cough or sore throat, reached approximately 8% nationwide, a rate not recorded since national surveillance began in 1997.

Flu seasons typically do not peak until January or February, and experts caution that initial dips in reported cases during holiday periods may not indicate a true peak.

A Deep Dive into the Numbers

Estimates for the current flu season have evolved significantly as the season progressed, reflecting the escalating impact:

  • Initial Estimates (December): At least 11 million illnesses, 120,000 hospitalizations, and 5,000 deaths.
  • Early January: Rose to at least 15 million illnesses, 180,000 hospitalizations, and 7,400 deaths.
  • Late January: Figures indicated 18 million illnesses, 230,000 hospitalizations, and 9,300 deaths.
  • Preliminary Season-End Projections: At least 27 million illnesses, 350,000 hospitalizations, and 22,000 deaths.

Children Most Affected

The impact on children has been particularly alarming this season:

  • Nine pediatric flu deaths were reported by early December, increasing to 101 by the season's conclusion.
  • The percentage of emergency department visits by children due to flu has exceeded the peak observed during the previous season.
  • Children are experiencing a 10-year high in doctor visits for flu-related symptoms, with more than 18% of visits for children under 4 years old being flu-related.
  • Last flu season (2024-2025) recorded 288 or 289 child flu deaths, the highest overall pediatric flu hospitalization rate and number of deaths since the 2009 H1N1 flu pandemic and since mandatory tracking began in 2004.

The Culprit: H3N2 and Vaccine Mismatch

The current rise in cases is primarily attributed to the prevalence of the A H3N2 flu virus, specifically the subclade K variant. This variant has been in international circulation since the summer and has historically been linked to higher rates of hospitalization and mortality among older individuals. Analysis of tested influenza viruses showed that over 90% of H3N2 infections identified were the subclade K variant.

Public health experts have indicated a "slight mismatch" or "mismatch" between this prevalent circulating strain and the strain included in this year's influenza vaccines. This occurred because the new flu strain emerged after the vaccine's formulation was determined.

Despite this mismatch, health officials emphasize that the vaccine provides protection against severe illness, hospitalization, and death, even if it does not offer 100% protection against infection.

Season-end data indicated vaccine effectiveness for preventing medical attention for flu was approximately 25-30% in adults and around 40% in children, compared to a typical target of 40-60%.

In late January, a slight increase in flu activity was observed, signaling a potential second peak driven by influenza B viruses, predominantly affecting school-aged children.

Strained Healthcare Systems

The high volume of respiratory illnesses, including flu, COVID-19, and Respiratory Syncytial Virus (RSV), has significantly impacted healthcare systems. Emergency departments reported high numbers of patients with respiratory symptoms. Pediatric flu hospitalizations doubled in some centers compared to the preceding period, occurring approximately one month earlier than the previous year. New York state health officials documented a record number of flu hospitalizations and infections in a single week in December.

A Triple Threat: Co-circulating Viruses

In addition to influenza, COVID-19 infections have also been rising, though generally remaining less frequent than flu cases this winter. RSV and norovirus have also been circulating, contributing to overall respiratory illness activity and leading to school closures in some states. The concurrent peaking of these viruses, which are often staggered, has contributed to a more severe cold and flu season.

Federal Shift in Childhood Flu Vaccine Guidance

The Department of Health and Human Services (HHS) and the CDC announced significant changes to childhood immunization guidelines during the flu season.

  • The Trump administration/HHS stated it would no longer recommend flu vaccinations for all U.S. children, indicating this decision should be made by parents and patients in consultation with their doctors.
  • The CDC later updated its recommended childhood vaccine schedule to suggest "shared clinical decision-making" with doctors for non-high-risk children regarding flu vaccination, alongside six other childhood immunizations. This policy change followed the administration's decision last year to cease recommending COVID-19 shots for healthy children.
  • A federal notice indicated that government Medicaid programs would no longer be required to report on immunization rates.

Health Secretary Robert F. Kennedy Jr. stated this was part of an initiative to separate the rating and payment of Medicaid doctors from their childhood vaccination rates, aiming to avoid "coercing doctors or families into accepting vaccines or penalizing physicians for respecting patient choice."

Medical Community Reactions

These changes prompted strong reactions from medical groups:

  • The American Academy of Pediatrics described the changes as "dangerous" and "irresponsible," expressing concern that they could create uncertainty and reduce childhood flu vaccinations.
  • Dr. Robert Hopkins, medical director of the National Foundation for Infectious Diseases, commented that the change in Medicaid reporting eliminated a significant data source for assessing efforts to protect children from vaccine-preventable diseases.

Acting CDC Director Jim O'Neill stated that current respiratory illness activity is comparable to last season's and that pediatric flu vaccination decisions should be based on individual patient characteristics. He also mentioned a new scientific review found no randomized controlled trials demonstrating a reduction of community transmission, hospitalizations, or mortality in children from the pediatric vaccine, a finding disputed by independent experts.

Despite these changes, flu vaccines continue to be covered by private insurers and federal programs, including Medicaid, the Children's Health Insurance Program, and the Vaccines for Children program.

Vaccination Efforts and Future Projections

The CDC recommends that individuals aged 6 months and older, with few exceptions, receive an annual flu vaccine. Vaccination rates for the season were around 42-43% for adults and children in December, with season-end estimates at 46.5% for adults and 48% for children. Of the pediatric flu deaths with known vaccination status, approximately 85-90% occurred in unvaccinated children.

Health officials anticipate that flu-like illnesses will continue to circulate, with the season's peak typically occurring in February. The World Health Organization (WHO) and a U.S. Food and Drug Administration advisory committee have recommended that vaccines for the 2026-27 northern hemisphere flu season specifically target the subclade K strain.